This Small Biotech Is Building on a Surprising Success

This Small Biotech Is Building on a Surprising Success

Source: 
Motley Fool
snippet: 

One of the surprises in AbbVie's fourth-quarter results that led to a 14% jump in the stock price the day they were announced was the success of its recently launched drug for treating hepatitis C virus (HCV), Mavyret. CEO Richard Gonzalez said the drug finished 2017 with a 32% market share in the U.S. and was a factor in the decision to increase sales guidance for 2018.